<DOC>
	<DOCNO>NCT02672527</DOCNO>
	<brief_summary>As transparency committee Haute Autorité de Santé point due lack data regard comparative trial Yondelis versus best supportive care , activity Yondelis soft tissue sarcoma remain assessed . For antineoplastic drug toxicity moderate . As previous study show , overall survival data patient advance metastatic STS poor prognosis despite improvement result last year . For example , median overall survival increase 12,3 month ( 1987-1991 ) 11,4 month ( 1992-1996 ) 18 month ( 2002-2006 ) . Considering late result without Trabectedin , investigator may consider compare Trabectedin best supportive care ethically acceptable long patient consent enter trial .</brief_summary>
	<brief_title>Trial Comparing Trabectedin Best Supportive Care Patients With Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Informed consent understood , agree sign 2 . Tolerance central venous line use Trabectedin infusion . 3 . Pathologically confirm diagnosis STS investigator centre level ( confirm Rrepps Network ) , except follow case : Low grade fibromyxoid sarcoma ( LGFMS ) , Giant Cells Fibroblastoma , Dermatofibrosarcoma protuberance ( DFSP ) , Angiomatoid fibrous histiocytoma , Alveolar Rhabdomyosarcoma Embryonal Rhabdomyosarcoma , Mesenchymal NonMesenchymal Chondrosarcoma , Extraskeletal Ewing Sarcoma / Primitive Neuroectodermal Tumour ( PNET ) , Desmoplastic small roundcell tumour ( DSRCT ) , GastroIntestinal Stromal Tumour ( GIST ) , Endometrial Stroma Sarcoma , Osteosarcoma . 4 . Histological sample available centralised histopathological diagnosis appropriate genetic diagnosis . 5 . Patient already receive 3 previous therapy line . Therefore , trabectedin might administer 2nd , 3rd 4th therapy line case metastatic STS . 6 . Measurable disease per RECIST ( Response Evaluation Criteria In Solid Tumors ) , confirm base objective data within 14 day prior study inclusion . 7 . Disease progression accord RECIST 1.1 confirm image evaluation within 14 day prior study inclusion comparatively image within previous 6 month . 8 . ECOG ( Eastern Cooperative Oncology Group ) Performance score : 0 1 . 9 . Normal cardiac function assess cardiac ultrasound examination MUltiple Gated Acquisition scan ( MUGA scan ) . 10 . Biological laboratory parameter meet follow criterion within 14 day prior study inclusion : neutrophil leucocyte ≥ 1500 /μL , haemoglobin ≥ 9,0 g/100 mL , platelet count 100 x 103 /μL AST ( aspartate aminotransferase ) ≤ 2.5 time investigator local laboratory upper normal limit ( UNL ) , ALT ( alanine aminotransferase ) ≤ 2.5 time investigator local laboratory UNL , Alkaline phosphatases ≤ 2.5 UNL , bilirubin ≤ UNL , CPK ≤ 2.5 time investigator laboratory UNL , albumin ≥ 25 g/L creatinine clearance measure calculate ( CockcroftGault formula ) ≥ 30 mL/min . 11 . Patient reach majority age time sign inform consent . 12 . Life expectancy least 3 month study entry . 13 . Patient cover health insurance system . 14 . All woman childbearing potential must negative serum pregnancy test within 14 day prior study inclusion . 1 . Hypersensitivity , history allergic reaction trabectedin 2 . History allergic reaction know hypersensitivity dexamethasone antiemetic agent belong triptan family ( i.e. , 5HT3 receptor antagonist ) . 3 . History allergic reaction know hypersensitivity contrast agent ( except patient 's tumour evaluate use MRI without contrast agent ) . 4 . Severe concomitant disease ( pulmonary fibrosis , interstitial pneumonitis , renal insufficiency , liver failure , cerebrovascular disease , malignant disease require blood transfusion , uncontrolled diabetes ) . 5 . Clinically significant abnormality electrocardiogram test , one follow clinically significant cardiac disease : Congestive cardiac insufficiency , Active coronary disease , Arrhythmia poorly control medicinal product , Myocardial infarction within one year prior study entry . 6 . Surgery general anaesthesia within 28 day prior study entry , exploratory surgery ( thoracotomy laparotomy ) within 28 day prior study entry , . 7 . Treatment one follow anticancer agent prior study entry : hormonotherapy within 14 day prior study entry , anticancer treatment ( chemotherapy , target therapy , biological advance therapy ) within 21 day prior study entry . 8 . Radiotherapy within 21 day prior study entry . 9 . History graft transplantation stem cell transplantation . 10 . Adverse reaction previous treatment , alopecia , longlasting , grade ≥ 2 severity accord CTCAE ( v. 4.0 ) criterion . 11 . Intercurrent infection require systemic antimicrobial treatment ( e.g. , associate fever ≥ 38° C ) , 12 . Patients HIV positive and/or viral antitherapy and/or hepatitis B and/or C. Systematic serology check status necessary . 13 . Brain metastasis , either symptomatic requiring treatment . 14 . History another cancer within 5 year prior study entry ( except intraepithelial neoplasm basocellular cancer , cure , e.g. , thanks surgical resection radiotherapy ) . 15 . Psychiatric disorder disturb informed consent process . 16 . Pregnant breastfeed woman ; man woman comply contraceptive measure follow time period : For men , full study 5 month last study treatment administration ; For woman , femmes , full study 3 month last study treatment administration . 17 . Other investigational treatment within 28 day prior study entry . 18 . Prior treatment trabectedin . 19 . Any clinical condition compatible adequate study conduct , accord investigator 's judgement . 20 . Patient administrative legal supervision , patient hospitalise without his/her consent purpose research , patient guardianship curator , unable express his/her consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>